3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl](2H4)ethyl}-9-hydroxy-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one

• ChemBase ID: 171277
• Molecular Formular: C23H27FN4O3
• Molecular Mass: 426.4838832
• Monoisotopic Mass: 426.20671896
• SMILES: C1CCn2c(C1O)nc(c(c2=O)CCN1CCC(CC1)c1noc2c1ccc(c2)F)C
• Canonical SMILES: Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2O
• InChI: InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3
• InChIKey: PMXMIIMHBWHSKN-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl](^2H₄)ethyl}-9-hydroxy-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one
• IUPAC Traditional name: 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl](^2H₄)ethyl}-9-hydroxy-2-methyl-6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one
• Synonyms: 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl-d4]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; Invega-d4; Paliperidone-d4; R 76477-d4; RO 76477-d4; Risperidone Imp. C (EP)-d4; rac 9-Hydroxy Risperidone-d4; 9-Hydroxyrisperidone-d4

Database IDs

• CAS Number: 1020719-55-4
• PubChem SID: 164227187
• PubChem CID: 25226608

CALCULATED PROPERTIES

• Acid pKa: 13.742356
• H Acceptors: 5
• H Donor: 1
• LogD (pH = 5.5): -1.3088015
• LogD (pH = 7.4): 0.37811172
• Log P: 1.7565552
• Molar Refractivity: 116.0414 cm^3
• Polarizability: 44.54549 Å^3
• Polar Surface Area: 82.17 Å^2
• Rotatable Bonds: 4
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: Chloroform; Dichloromethane; Methanol
• Apperance: Beige Solid; Off White to Light Orange Coloured Solid
• Melting Point: 158-160°C; 162-165°C

Safety Information

• Storage Condition: -20°C Freezer

DETAILS

Toronto Research Chemicals - H953352

A deuterated metabolite of Risperidone (R525000), a combined serotonin (5-HT2) and dopamine (D2) receptor antagonist.

Toronto Research Chemicals - P141002

A deuterated analog of Paliperidone, a combined serotonin (5-HT2) and dopamine (D2) receptor antagonist.

REFERENCES

• Tiberghien, F., et al.: Anticancer Drugs, 7, 568 (1996)
• Kansy, M., et al.: J. Med. Chem., 41, 1007 (1996)
• Kerns, E., et al.: J. Pharm. Sci., 90, 1838 (1996)
• Kerr, K., et al.: J. Biol. Chem., 276, 8657 (1996)
• Doran, A., et al.: Drug Metab. Dispos., 33,
• Kerr, K., et al.: J. Biol. Chem., 276, 8657 (1996)
• Doran, A., et al.: Drug Metab. Dispos., 33,
• Kerns, E., et al.: J. Pharm. Sci., 90, 1838 (1996)
• Tiberghien, F., et al.: Anticancer Drugs, 7, 568 (1996)
• Kansy, M., et al.: J. Med. Chem., 41, 1007 (1996)